Small molecule inhibitors of the Menin‐KMT2A interaction (i.e. Revumenib) (Fig. 4A) have recently been developed that have shown promise in preclinical studies of AML driven by both KMT2A‐oncofusions and NPM1C mutations. This evidence concerns the gene KMT2A and acute myeloid leukemia.